Stock listing
Frankfurt:2O90 Renalytix PLC Aktie
German listing (Frankfurt) of Renalytix PLC · home listing LSE:RENX
Follow Renalytix PLC into a list and get an email when it puts out news.
Home listing price · LSE:RENX
5.20p GBX (pence) -0.15 (-2.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:RENX
- Day range
- 5.01p – 5.50p GBX (pence)Nov 20, 2026
- Volume
- 1.15M sharesNov 20, 2026
- Market cap
- £34.86M GBPAt the close on Nov 20, 2026 · price × 670.5M shares outstanding
- 52-week range
- 1.60p – 7.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £78,687 GBPMedian day 614,627 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:RENX · Home | 5.20p GBX (pence) | -0.15 (-2.8%) | 1,152,229 | 5.35p | 5.50p | 5.01p | 5.35p | Close on Nov 20, 2026 |
| OTC:RNLXY | $3.45 USD | -0.05 (-1.4%) | 100 | $3.45 | $3.45 | $3.45 | $3.50 | Close on Nov 20, 2026 |
| OTC:RENXF | $0.066 USD | 0.000 (0.0%) | — | $0.066 | $0.066 | $0.066 | $0.066 | Close on Nov 6, 2026 |
| Frankfurt:2O9 | €0.061 EUR | -0.001 (-0.8%) | — | €0.061 | €0.061 | €0.061 | €0.061 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:RENX · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 5.20p | -0.15 | -2.8% | 5.35p | 5.50p | 5.01p | 1,152,229 | |
| 5.35p | 0.00 | 0.0% | 5.35p | 5.50p | 5.32p | 55,216 | |
| 5.35p | -0.05 | -0.9% | 5.40p | 5.50p | 5.215p | 644,990 | |
| 5.40p | 0.00 | 0.0% | 5.40p | 5.40p | 5.303p | 46,134 | |
| 5.40p | 0.00 | 0.0% | 5.40p | 5.60p | 5.281p | 193,359 | |
| 5.40p | 0.00 | 0.0% | 5.40p | 5.465p | 5.25p | 163,589 | |
| 5.40p | 0.00 | 0.0% | 5.40p | 5.60p | 5.40p | 219,557 | |
| 5.40p | -0.05 | -0.9% | 5.45p | 5.60p | 5.272p | 863,587 | |
| 5.45p | -0.05 | -0.9% | 5.50p | 5.52p | 5.30p | 337,776 | |
| 5.50p | -0.05 | -0.9% | 5.55p | 5.70p | 5.321p | 494,824 | |
| 5.55p | 0.00 | 0.0% | 5.55p | 5.70p | 5.40p | 283,416 | |
| 5.55p | +0.10 | +1.8% | 5.50p | 5.58p | 5.413p | 131,426 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.48p | 5.394p | 369,695 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.54p | 5.363p | 448,082 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.60p | 5.30p | 1,144,502 | |
| 5.45p | -0.15 | -2.7% | 5.60p | 5.70p | 5.428p | 595,142 | |
| 5.60p | -0.35 | -5.9% | 5.64p | 5.64p | 5.153p | 2,984,229 | |
| 5.95p | 0.00 | 0.0% | 5.95p | 6.05p | 5.804p | 614,627 | |
| 5.95p | -0.05 | -0.8% | 6.00p | 6.10p | 5.90p | 914,170 | |
| 6.00p | +0.20 | +3.4% | 5.80p | 6.10p | 5.60p | 2,483,906 | |
| 5.80p | +0.45 | +8.4% | 5.35p | 5.90p | 5.20p | 2,900,799 | |
| 5.35p | 0.00 | 0.0% | 5.35p | 5.475p | 5.20p | 266,695 | |
| 5.35p | -0.10 | -1.8% | 5.45p | 5.50p | 5.21p | 1,155,417 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.487p | 5.30p | 184,469 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.50p | 5.30p | 253,730 | |
| 5.45p | 0.00 | 0.0% | 5.45p | 5.60p | 5.30p | 1,439,646 | |
| 5.45p | +0.10 | +1.9% | 5.35p | 5.54p | 5.30p | 99,467 | |
| 5.35p | 0.00 | 0.0% | 5.35p | 5.60p | 5.10p | 350,049 | |
| 5.35p | +0.05 | +0.9% | 5.30p | 5.60p | 5.10p | 795,886 | |
| 5.30p | -0.20 | -3.6% | 5.40p | 5.50p | 5.10p | 1,404,443 | |
| 5.50p | -0.30 | -5.2% | 5.80p | 6.00p | 5.15p | 1,657,860 | |
| 5.80p | -0.15 | -2.5% | 5.95p | 6.00p | 5.70p | 439,972 | |
| 5.95p | -0.05 | -0.8% | 6.00p | 6.20p | 5.728p | 695,636 | |
| 6.00p | 0.00 | 0.0% | 6.00p | 6.20p | 5.80p | 194,466 | |
| 6.00p | 0.00 | 0.0% | 6.00p | 6.09p | 5.80p | 880,986 | |
| 6.00p | -0.10 | -1.6% | 6.05p | 6.30p | 5.80p | 1,200,742 | |
| 6.10p | +0.05 | +0.8% | 6.05p | 6.30p | 5.80p | 2,385,600 | |
| 6.05p | -0.10 | -1.6% | 6.15p | 6.30p | 5.752p | 3,019,439 | |
| 6.15p | 0.00 | 0.0% | 6.15p | 6.50p | 5.80p | 788,003 | |
| 6.15p | 0.00 | 0.0% | 6.15p | 6.15p | 5.835p | 452,742 | |
| 6.15p | +0.15 | +2.5% | 6.15p | 6.15p | 5.80p | 75,944 | |
| 6.00p | -0.25 | -4.0% | 6.25p | 6.50p | 5.88p | 465,342 | |
| 6.25p | 0.00 | 0.0% | 6.25p | 6.25p | 6.00p | 1,466,487 | |
| 6.25p | 0.00 | 0.0% | 6.25p | 6.50p | 6.00p | 378,529 | |
| 6.25p | +0.10 | +1.6% | 6.15p | 6.50p | 5.80p | 506,370 | |
| 6.15p | -0.10 | -1.6% | 6.25p | 6.50p | 6.00p | 776,610 | |
| 6.25p | +0.30 | +5.0% | 5.85p | 6.497p | 5.50p | 962,040 | |
| 5.95p | -0.45 | -7.0% | 6.30p | 6.40p | 5.70p | 1,174,315 | |
| 6.40p | +0.10 | +1.6% | 6.35p | 6.57p | 6.20p | 7,794,978 | |
| 6.30p | +0.70 | +12.5% | 5.60p | 6.50p | 5.50p | 16,158,342 | |
| 5.60p | +0.20 | +3.7% | 5.40p | 6.00p | 5.20p | 2,530,386 | |
| 5.40p | 0.00 | 0.0% | 5.35p | 5.70p | 5.20p | 7,080,792 | |
| 5.40p | +1.25 | +30.1% | 5.75p | 6.00p | 5.00p | 4,422,050 | |
| 4.15p | 0.00 | 0.0% | 4.15p | 4.15p | 4.15p | 0 | |
| 4.15p | 0.00 | 0.0% | 4.15p | 4.30p | 4.03p | 54,960 | |
| 4.15p | -0.10 | -2.4% | 4.25p | 4.30p | 4.00p | 470,800 | |
| 4.25p | -0.05 | -1.2% | 4.30p | 4.30p | 4.20p | 83,188 | |
| 4.30p | +0.05 | +1.2% | 4.25p | 4.675p | 4.20p | 2,370,623 | |
| 4.25p | +0.40 | +10.4% | 3.85p | 4.50p | 3.70p | 928,053 | |
| 3.85p | -0.05 | -1.3% | 3.90p | 4.00p | 3.70p | 131,184 | |
| 3.90p | -0.05 | -1.3% | 3.95p | 4.10p | 3.70p | 290,150 |
- Ticker
- Frankfurt:2O90
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 18, 2026
Notice of 2026 Annual General Meeting
Latest earnings call · Sep 29, 2026
Renalytix (LSE:RENX) — Company Update
Replay and transcript
Latest news
Notice of 2026 Annual General Meeting
Nov 18, 2026
Closed 5.35p (0.0%) on Nov 18, 2026
Holding(s) in Company
Nov 16, 2026
Closed 5.35p (-0.9%) on Nov 17, 2026
Conference attendance at Mello2026 Investor event
Nov 10, 2026
Closed 5.40p (-0.9%) on Nov 10, 2026
Publication of Equity Research
Nov 9, 2026
Closed 5.45p (-0.9%) on Nov 9, 2026
Unaudited Twelve Months to 30 June 2026 Report
Oct 28, 2026
Closed 5.60p (-5.9%) on Oct 28, 2026
US Kidney Care National Plan
Oct 22, 2026
Closed 5.80p (+8.4%) on Oct 22, 2026
Director/PDMR Shareholding (Replacement)
Oct 2, 2026
Closed 6.00p (0.0%) on Oct 5, 2026
Director/PDMR Shareholding
Oct 1, 2026
Closed 6.00p (0.0%) on Oct 2, 2026
Renalytix PLC on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 36 in the last 12 months · 279 in all · newest Nov 18, 2026 · oldest 2018
- Calls
- 17 calls with a replay · 17 with a transcript · latest Sep 29, 2026
- Decks
- 2 decks · latest September 2025
Where Renalytix PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:RENX · Home listing | LSE | United Kingdom | GBX |
| OTC:RNLXY | OTC | United States | USD |
| LS Exchange:A2N765 | LS Exchange | Germany | EUR |
| gettex:2O9 | gettex | Germany | EUR |
| Aquis:RENXL | Aquis | United Kingdom | GBX |
| OTC:RENXF | OTC | United States | USD |
| Frankfurt:2O9 | Frankfurt | Germany | EUR |
| Frankfurt:2O90 · This page | Frankfurt | Germany | EUR |
| gettex:A41WQD | gettex | Germany | EUR |
| Lang & Schwarz:A2N765 | Lang & Schwarz | Germany | EUR |
| Lang & Schwarz:A41WQD | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41WQD | LS Exchange | Germany | EUR |
| Munich:2O9 | Munich | Germany | EUR |
| Stuttgart:2O9 | Stuttgart | Germany | EUR |
Valuation
EV/sales 15.1× against a median of 1.2×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- £34.56M GBP
- P/E
- Loss
- EV/sales
- 15.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 40.0%
- Operating margin
- −573.3%
- Net margin
- −680.0%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Renalytix PLC · LSE:RENX | US$45.66M | US$45.26M | n/a | 15.1× | n/a | n/a | −680.0% | n/a | n/a |
| Celemics, Inc. · KRX:331920 | US$49.19M | US$32.45M | n/a | 8.4× | n/a | 2.2× | −260.9% | 0.5× | n/a |
| Lumos Diagnostics Holdings Ltd. · ASX:LDX | US$47.13M | US$37.64M | n/a | 2.8× | n/a | 2.1× | −37.5% | 0.3× | n/a |
| Labiana Health SA · BME:LAB | US$44.35M | US$70.57M | 15.7× | 0.9× | 5.8× | 8.0× | 3.4% | 5.9× | n/a |
| Access Bio, Inc. · KRX:950130 | US$44.15M | −US$191.0M | n/a | −10.8× | n/a | 0.1× | −468.1% | 0.0× | n/a |
| EDX Medical Group plc · LSE:EDX | US$43.78M | US$39.96M | n/a | 92.3× | n/a | 15.4× | n/a | 0.0× | n/a |
| Osang Healthcare Co. Ltd. · KRX:036220 | US$42.35M | US$24.18M | n/a | 0.3× | n/a | 0.2× | −8.8% | 0.1× | n/a |
| ABL Diagnostics SA · EURONEXT:ABLD | US$41.27M | US$42.32M | 38.1× | 5.5× | 42.8× | 5.3× | 14.2% | 0.3× | n/a |
| hVIVO plc · LSE:HVO | US$41.02M | US$42.24M | n/a | 0.7× | 7.5× | 1.0× | −12.8% | 0.4× | n/a |
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| CytoGen, Inc. · KRX:217330 | US$38.58M | US$31.66M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| Median of the others | US$43.06M | US$38.80M | 26.9× | 1.2× | 18.0× | 2.1× | −13.2% | 0.3× | 1.34 |
Team and board
Officers
| Officer | Role |
|---|---|
| James McCullough | MBA, CEO |
| Joel R. Jung | MBA, Interim CFO |
| Howard Doran | President |
| Elise Wilfinger | Chief Strategy & Marketing Officer |
| Fergus Fleming | CTO |
| Michael J. Donovan | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Julian Baines | Chairman |
| Catherine Coste | |
| Christopher Mills | |
| Erik Lium | Board Member |
| Robert Naylor |
Events
Calls
| Call | When | Status |
|---|---|---|
| Renalytix (LSE:RENX) — Company Update | Tue, Sep 29, 2026 · 11:00 AM ET | Replay |
| Renalytix (LSE:RENX) Q2 2025 Earnings Call | Tue, Mar 18, 2025 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q3 2024 Earnings Call | Wed, May 15, 2024 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q1 2024 Earnings Call | Tue, Nov 14, 2023 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q4 2023 Earnings Call | Thu, Sep 28, 2023 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q3 2023 Earnings Call | Fri, Jun 09, 2023 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q2 2023 Earnings Call | Thu, Mar 30, 2023 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q1 2023 Earnings Call | Wed, Nov 30, 2022 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q4 2022 Earnings Call | Mon, Oct 31, 2022 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q3 2022 Earnings Call | Thu, Jun 30, 2022 · 8:30 AM ET | Replay |
All 17 calls
| Call | When | Status |
|---|---|---|
| Renalytix (LSE:RENX) Q2 2022 Earnings Call | Thu, Mar 31, 2022 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q1 2022 Earnings Call | Tue, Dec 07, 2021 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q4 2021 Earnings Call | Thu, Oct 21, 2021 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q3 2021 Earnings Call | Tue, Jun 15, 2021 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) Q2 2021 Earnings Call | Tue, Mar 02, 2021 · 8:30 AM ET | Replay |
| Renalytix (LSE:RENX) — Financial results for the full year ended June 30, 2020 | Tue, Oct 27, 2020 · 12:30 PM ET | Replay |
| Renalytix (LSE:RENX) Q4 2020 Earnings Call | Tue, Oct 27, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | May 13, 2026 | 0.0% |
| Quarter to Sep 30, 2025 | Nov 4, 2025 | −1.8% |
| Quarter to Mar 31, 2025 | Jun 17, 2025 | 0.0% |
| Q2 2025 | Mar 18, 2025 · Before open | 0.0% |
| Q1 2025 | Oct 1, 2024 · Before open | +6.3% |
| Q3 2024 | May 15, 2024 · After close | 0.0% |
| Q2 2024 | Feb 15, 2024 · After close | −10.9% |
| Q1 2024 | Nov 14, 2023 · Before open | −26.7% |
| Q4 2023 | Sep 28, 2023 · Before open | −25.8% |
| Q3 2023 | Jun 9, 2023 · Before open | −5.7% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Mar 30, 2023 · After close | −2.9% |
| Q1 2023 | Nov 30, 2022 · Before open | +6.9% |
| Q4 2022 | Sep 30, 2022 | −2.5% |
| Q3 2022 | Jun 30, 2022 · Before open | −37.3% |
| Q2 2022 | Mar 31, 2022 · Before open | 0.0% |
| Q1 2022 | Dec 7, 2021 | −2.7% |
| Q3 2021 | Jun 15, 2021 | +2.2% |
| Q2 2021 | Mar 2, 2021 | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2025) | Investor deck | 10 slides | September 2025 |
| H1 FY2025 Earnings Presentation | Earnings | 18 slides | March 2025 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Retail Offer Shares Closed: £1M raised · £0.06 a share | Sep 28, 2026 | US$1.35M |
| Private placement of new ordinary shares Closed: £10.1M raised · £0.06 a share · Oberon Capital +1 Dealers: Oberon Capital (lead), SP Angel Corporate Finance LLP | Sep 28, 2026 | US$13.66M |
| Private placement of new Ordinary Shares Closed: £7.05M raised · GBX 9.5 a share · Oberon Capital +2 Dealers: Oberon Capital (lead), SP Angel Corporate Finance LLP, Winterflood Securities Ltd Buyers: Julian Baines (105,263 shares; 0.48% post Admission); Christopher Mills (2,500,000 shares; 4.21% post Admission); Robert Naylor (105,263 shares; 0.17% post Admission); Catherine Coste (105,263 shares; 0.1% post Admission) Insiders: Directors Julian Baines, Christopher Mills, Robert Naylor and Catherine Coste participated in the Fundraise Use of proceeds: Support growth and the new collaboration with Tempus AI | Sep 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Renalytix AI plc. Final prospectus filed on Jul 17, 2020.
- Shares offered
- 11,000,000 ordinary shares
- Underwriters' option
- Up to 822,750 more shares
- Underwriters
- J.P. Morgan, Stifel · In the order on the cover
- Shares delivered
- On or about Jul 21, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 15, 2020 |
| Filed publicly | Jun 24, 2020 |
| Amended once | Jul 13, 2020 |
| Shares registered with an exchange | Jul 13, 2020 |
| Declared effective by the SEC | Jul 16, 2020 |
| Final prospectus, with the price | Jul 17, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 17, 2020 |
| CERT · Exchange's certificate of listing | Jul 17, 2020 |
| FWP · Free writing prospectus | Jul 17, 2020 |
| EFFECT · Notice that a registration is effective | Jul 16, 2020 |
| CORRESP · Letter to the SEC | Jul 14, 2020 |
| CORRESP · Letter to the SEC | Jul 14, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2020 |
| F-1/A · Registration statement, amended | Jul 13, 2020 |
| CORRESP · Letter to the SEC | Jul 6, 2020 |
| UPLOAD · Letter from the SEC | Jul 1, 2020 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 24, 2020 |
| F-1 · Registration statement | Jun 24, 2020 |
| UPLOAD · Letter from the SEC | Jun 11, 2020 |
| DRS · Draft registration statement | May 15, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 17, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00M | 2.29M | 3.40M | 2.97M | 1.49M | 0 | ||
| Cost of revenue | 1.80M | 2.13M | 2.68M | 2.10M | 858.0K | 0 | ||
| Gross profit | 1.20M | 156.0K | 720.0K | 874.0K | 633.0K | 0 | ||
| Research and development | 900.0K | 9.29M | 14.3M | 14.6M | 10.0M | 4.57M | 4.32M | |
| Selling, general and administrative | 4.90M | 19.8M | 28.7M | 13.0M | 8.37M | 1.25M | ||
| Operating income | -17.2M | -29.6M | -42.2M | -53.2M | -31.9M | -10.3M | -42.3M | -418.0K |
| Depreciation and amortization | 0 | 364.0K | 508.0K | 489.0K | 282.0K | 70.0K | 31.0K | 1.25M |
| EBITDA | -17.2M | -29.2M | -41.7M | -52.7M | -31.6M | -10.2M | -42.3M | 836.0K |
| Interest expense | 500.0K | 0 | 2.00K | 2.00K | 3.00K | |||
| Income before tax | -21.8M | -33.5M | -45.6M | -45.3M | -35.3M | -9.84M | -42.3M | -418.0K |
| Income tax | -1.40M | 4.00K | 2.00K | 25.0K | 0 | 0 | ||
| Net income | -20.4M | -33.5M | -45.6M | -45.3M | -35.3M | -9.84M | -42.3M | -1.25M |
| Earnings per share, basic | -0.21 | -0.31 | -0.55 | -0.62 | -0.49 | -0.17 | -0.99 | -0.03 |
| Earnings per share, diluted | -0.31 | -0.55 | -0.67 | -0.49 | -0.17 | -0.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.60M | 4.68M | 24.7M | 41.3M | 65.1M | 13.3M | 8.20M | 41.5K |
| Short-term investments | 100.0K | 700.0K | 1.46M | 2.74M | 0 | 982.0K | 994.0K | |
| Receivables | 600.0K | 722.0K | 776.0K | 901.0K | 594.0K | 15.1K | ||
| Inventory | 200.0K | 300.0K | 718.0K | 1.16M | 353.0K | -7.00K | ||
| Current assets | 5.80M | 6.12M | 26.9M | 44.8M | 66.8M | 14.8M | 9.42M | 56.6K |
| Property, plant and equipment | 216.0K | 1.03M | 1.37M | 2.49M | 1.66M | 278.0K | ||
| Goodwill | 23.1B | 23.1B | 23.1B | |||||
| Total assets | 6.10M | 7.97M | 30.6M | 50.1M | 78.6M | 20.9M | 9.70M | 56.6K |
| Accounts payable | 2.60M | 2.61M | 2.94M | 1.38M | 1.40M | 2.22M | 317.0K | 10.0K |
| Current liabilities | 4.80M | 11.5M | 16.1M | 11.8M | 7.06M | 3.29M | 1.15M | 66.0K |
| Long-term debt | 8.30M | 4.33M | 7.49M | 7.68M | 0 | |||
| Total debt | 8.30M | 8.54M | 12.2M | 12.3M | 352.0K | 66.0K | ||
| Total liabilities | 13.1M | 15.8M | 23.7M | 19.5M | 7.12M | 4.97M | 1.15M | 66.0K |
| Shareholders' equity | -7.00M | -7.85M | 6.97M | 30.6M | 71.5M | 15.9M | 8.55M | -349.0K |
| Shares outstanding | 97.3M | 154.4M | 93.8M | 74.8M | 72.2M | 59.4M | 53.8M | 41.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -17.9M | -30.1M | -34.1M | -45.9M | -28.4M | -9.52M | -6.16M | -422.0K |
| Capital spending | -6 | -4.00K | 0 | -557.0K | -773.0K | -804.0K | -309.0K | 0 |
| Free cash flow | -17.9M | -30.1M | -34.1M | -46.5M | -29.2M | -10.3M | -6.46M | -422.0K |
| Cash from investing | -4.00K | 0 | -662.0K | -751.0K | -1.17M | -12.3M | ||
| Cash from financing | 16.0M | 10.3M | 16.4M | 25.6M | 77.2M | 15.9M | 27.4M | 504.0K |
| Dividends paid | -4.64B | -5.10B | -5.23B | |||||
| Share buybacks | -1.62B | -3.44B | 5.23B | |||||
| Change in cash | -1.10M | -20.0M | -16.7M | -23.8M | 51.8M | 5.09M | 8.12M | 82.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 23, 2026 | Big-stake notice | SEC |
| F-6 POS | Dec 3, 2025 | Other filings | SEC |
| F-6 POS | Sep 4, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 30, 2025 | Offer document | SEC |
| 15-12G | Jul 30, 2025 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| POS AM · Amendment to an effective registration | Jul 29, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 29, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 29, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 29, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 29, 2025 | Offer document | SEC |
| S-8 POS | Jul 25, 2025 | Offer document | SEC |
| S-8 POS | Jul 25, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 16, 2025 | Current report | SEC |
| 8-K · Current report | Dec 20, 2024 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Nov 25, 2024 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Nov 19, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 19, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2024 | Explanation request | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 12, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 5, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 11, 2024 | Meeting notice | SEC |
| 25 | Oct 7, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 2, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 1, 2024 | Results | SEC |
| 10-K · Annual report | Sep 30, 2024 | Annual report | SEC |
| 8-K · Current report | Aug 27, 2024 | Current report | SEC |
| 8-K · Current report | Jul 15, 2024 | Financing | SEC |
| EFFECT · Notice that a registration is effective | Jul 1, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jun 28, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jun 25, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Jun 25, 2024 | Current report | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| S-3/A · Registration statement, amended | Jun 14, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Jun 11, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 5, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Jun 5, 2024 | Insider trade | SEC |
| 8-K · Current report | May 28, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | May 15, 2024 | Offer document | SEC |
| 8-K · Current report | May 15, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 424B3 · Prospectus | May 7, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 26, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 26, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 25, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 23, 2024 | Material contract | SEC |
| S-3 · Registration statement | Apr 17, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 10, 2024 | Financing | SEC |
| 8-K · Current report | Apr 9, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Apr 9, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Apr 4, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Mar 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 29, 2024 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 21, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 19, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 14, 2024 | Current report | SEC |
| 8-K · Current report | Mar 13, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 8-K · Current report | Feb 29, 2024 | Current report | SEC |
| 8-K · Current report | Feb 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 9, 2024 | Current report | SEC |
| 8-K · Current report | Jan 17, 2024 | Current report | SEC |
| 8-K · Current report | Jan 10, 2024 | Current report | SEC |
| 8-K · Current report | Dec 29, 2023 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Financing | SEC |
| 8-K · Current report | Dec 18, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 8, 2023 | Meeting notice | SEC |
| 8-K · Current report | Dec 8, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Nov 17, 2023 | Annual report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| DEFR14A | Nov 13, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 13, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 3, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 8-K · Current report | Oct 24, 2023 | Management or board change | SEC |
| 8-K · Current report | Oct 17, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2023 | Other filings | SEC |
| 10-K/A · Annual report, amended | Oct 5, 2023 | Annual report | SEC |
| CORRESP · Letter to the SEC | Oct 5, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| RW WD | Oct 2, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 2, 2023 | Other filings | SEC |
| RW · Request to withdraw a registration | Oct 2, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 2, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 28, 2023 | Results | SEC |
| S-3 · Registration statement | Sep 28, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 28, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 28, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 28, 2023 | Offer document | SEC |
| 10-K · Annual report | Sep 28, 2023 | Annual report | SEC |
| 8-K · Current report | Sep 22, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2023 | Management or board change | SEC |
| 8-K · Current report | Aug 21, 2023 | Current report | SEC |
| 8-K · Current report | Jul 17, 2023 | Current report | SEC |
| 4 · Change in ownership | Jul 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jul 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 9, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 9, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 22, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 11, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 11, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 11, 2023 | Other filings | SEC |
| 424B3 · Prospectus | May 10, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 8, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 5, 2023 | Other filings | SEC |
| F-3 · Registration statement | May 2, 2023 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Mar 30, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 27, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 21, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 10, 2023 | Current report | SEC |
| SC 13D · Big-stake notice | Feb 17, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Feb 10, 2023 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 8, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 20, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 30, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 29, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 22, 2022 | Current report | SEC |
| 20-F · Annual report | Oct 31, 2022 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Oct 25, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 21, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 17, 2022 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 3, 2022 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Aug 1, 2022 | Offer document | SEC |
| 20-F/A · Annual report, amended | Aug 1, 2022 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 27, 2022 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 7, 2022 | Other filings | SEC |
| 424B3 · Prospectus | Jun 6, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 2, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 1, 2022 | Other filings | SEC |
| F-3 · Registration statement | May 27, 2022 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | May 27, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 27, 2022 | Big-stake notice | SEC |
| 6-K/A · Report of a foreign issuer, amended | Apr 29, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 1, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 31, 2022 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 11, 2022 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 1, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2022 | Other filings | SEC |
| 20-F/A · Annual report, amended | Jan 27, 2022 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Jan 24, 2022 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 20, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 7, 2021 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 30, 2021 | Current report | SEC |
| 20-F · Annual report | Oct 21, 2021 | Annual report | SEC |
This page holds 200 of 233 filings. Open Filings
Cap table
Built by 6ix from Renalytix PLC’s releases · as of Sep 28, 2026
- Common shares
- 670,459,333
- Fully diluted
- 670,459,333
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 670,459,333 | Sep 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 670,459,333 |
| Sep 28, 2026 | 423,376,193 |
| Sep 28, 2026 | 417,040,486 |
| Jun 30, 2026 | 409,540,486 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Timothy J Scannell Other companies: Masimo Corporation (Director · Since at least Oct 16, 2024); NovoCure Limited (Director · Since at least Feb 5, 2021); Insulet Corporation (Director · Since at least Aug 12, 2014); EXACT Sciences Corporation (Director · Oct 31, 2023 – Oct 31, 2023 · Past); Molekule Group Inc. (Director · May 11, 2022 – Jun 1, 2022 · Past); Stryker Corporation (President and COO · Dec 1, 2008 – Aug 1, 2021 · Past) | Director · Jul 1, 2023 – Jul 1, 2023 · Past |
| Catherine Coste Other companies: BioLife Solutions, Inc. (Director · Since at least Mar 18, 2025); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); Biomerica, Inc. (Director · Oct 26, 2020 – Dec 13, 2024 · Past) | Director · Since at least Jul 1, 2023 |
| Thomas H McLain Other companies: Aspira Women's Health Inc. (President & CEO · Mar 18, 2013 – Mar 27, 2014 · Past); Eastman Chemical Company (Director · Apr 3, 2006 – Nov 30, 2011 · Past); Vaxart, Inc. (Chairman, CEO & President, Director · Dec 31, 2005 – Dec 30, 2006 · Past) | President · Jul 1, 2023 – Jul 10, 2023 · Past |
| Daniel J Levangie Other companies: EXACT Sciences Corporation (Director · Since at least Jul 23, 2015); Insulet Corporation (EVP & President, Drug Delivery · Feb 23, 2016 – Apr 30, 2016 · Past) | Director · Jul 1, 2023 – Nov 20, 2023 · Past |
| Howard Doran Jr Other companies: LipoScience Inc (President and CEO, Director · Feb 3, 2014 – Nov 20, 2014 · Past); Hologic Inc (SVP, Diagnostics Products · Oct 22, 2007 – Mar 12, 2010 · Past) | Chief Business Officer · Sep 1, 2023 – Nov 20, 2023 · Past |
| Erik Lium Other companies: Trellus Health PLC (Non-Executive Director · Since at least Nov 5, 2026) | Board Member · Since at least Jul 1, 2023 |
| Joel R. Jung Other companies: Minerva Surgical, Inc. (CFO · Oct 21, 2021 – May 2, 2022 · Past) | MBA, Interim CFO · Since at least May 27, 2024 |
| O James Sterling Other companies: Bluebird bio Inc (Chief Financial Officer · Since at least Jun 10, 2024) | Chief Financial Officer · Jul 1, 2023 – Jul 6, 2023 · Past |
| Chirag R Parikh | Director · Jul 1, 2023 – Nov 20, 2023 · Past |
| Christopher Mills | Director · Since at least Jul 1, 2023 |
All 17 people
| Person | Seat |
|---|---|
| Elise Wilfinger | Chief Strategy & Marketing Officer · Since at least May 12, 2026 |
| Fergus Fleming | CTO · Since at least Jul 1, 2023 |
| Howard Doran | President · Since at least Dec 30, 2024 |
| James McCullough | MBA, CEO · Since at least Jul 1, 2023 |
| Julian Baines | Chairman · Since at least Sep 3, 2026 |
| Michael J. Donovan | Chief Medical Officer · Since at least Jul 1, 2023 |
| Robert Naylor | Director · Since at least Dec 9, 2025 |
Log in to ask 6ix AI your own questions about Renalytix PLC.